CLASS II ONGOING Device recall · Reported 2 Oct 2024 · FDA Enforcement Report

Creatine Kinase (CK) used on cobas c 311/501/502 recalled

Roche Diagnostics Operations is recalling Creatine Kinase (CK) used on cobas c 311/501/502 and Cobas Integra 400 plus-In vitro test, distributed nationwide in the US. The recall was initiated on 15 Aug 2024 and the FDA has classified it as Class II.

Check your package

Lot, batch or date codesUDI-DI: 04015630940806 Lot Number: 755471 Exp. Date: 06/30/2024
Quantity recalled6504 units

Stop using the device if the notice says to, and contact the manufacturer or your healthcare provider for the correction or replacement.

Recall details

Recall number
Z-3187-2024
FDA event ID
95221
Recalling firm
Roche Diagnostics Operations, Indianapolis, IN
Classification
Class II
Status
Ongoing
Recall initiated
15 Aug 2024
FDA classified
20 Sep 2024
Reported
2 Oct 2024
Type
Voluntary: Firm initiated
Customers notified by
Letter
Reason category
Potency & Assay

Timeline

15 Aug 2024Recall initiated by company
20 Sep 2024Classified by FDA+36 days
2 Oct 2024Published in enforcement report+12 days

Companies usually start a recall weeks before the FDA classifies and publishes it; the gap above is that lag.

Reason for recall

Creatine Kinase (CK) Assay Abnormal calibrations on the cobas¿ c 311/501/502 and COBAS INTEGRA 400 plus Analyzers may lead to erroneous results and misdiagnosis.

Potency and specification recalls happen when a batch tests outside its approved limits for strength, purity or dissolution, which can mean the dose delivered is higher or lower than labelled.

Product as listed by the FDA

Creatine Kinase (CK) used on cobas c 311/501/502 and COBAS INTEGRA 400 plus-In vitro test for the quantitative determination of creatine kinase (CK) in human serum and plasma. Catalog Number: 07190794190

Where it was distributed

US Nationwide distribution.

Nationwide

Questions about this recall

Why was it recalled?

Creatine Kinase (CK) Assay Abnormal calibrations on the cobas¿ c 311/501/502 and COBAS INTEGRA 400 plus Analyzers may lead to erroneous results and misdiagnosis.

Which lots are affected?

UDI-DI: 04015630940806 Lot Number: 755471 Exp. Date: 06/30/2024

Where was it sold?

US Nationwide distribution.

What should I do if I have it?

Stop using the device if the notice says to, and contact the manufacturer or your healthcare provider for the correction or replacement.

What does Class II mean?

Class II means the product may cause temporary or medically reversible health problems, or the probability of serious harm is remote.

Read the official FDA notice · Source record retrieved 26 Sep 2026. The FDA describes openFDA data as unvalidated; the official notice takes precedence. This page reports the record and gives no medical advice.

More recalls from Roche Diagnostics Operations

All 127

Other Test Kits & Diagnostics recalls

All 2,663